Regulatory Status AOD-9604 is not an FDA-approved drug for any indication and has not been shown to be safe or effective for any human use
Heres a list of important things to consider when deciding whether or not to stop a seizure medication: Duration of seizure freedom (longer seizure-free period, often 25 years, lowers recurrence risk) Type of epilepsy syndrome or seizure classification Age at seizure onset (childhood-onset epilepsies often have better remission rates) Presence of structural brain disease (tumor, stroke, traumatic brain injury, cortical malformation) Number of antiseizure medications required for seizure control (monotherapy vs polytherapy) Seizure frequency prior to achieving control Duration of epilepsy before remission occurred Patient safety considerations if a seizure were to recur (driving, occupational risks, injury risk) Adverse effects or medication burden (cognitive effects, drug interactions, bone health concerns, teratogenic risk) I also wanted to discuss individual agents when considering whether or not to taper seizure medications and how that is typically done
By blocking NNMT, 5-Amino-1MQ helps preserve NAD, which supports metabolism, energy production, and cellular repair
BPC-157 (5mg Vial) Dosage Protocol BPC-157 is a synthetic pentadecapeptide derived from a protein in gastric juice, studied preclinically for tissue repair, recovery from soft-tissue injury, and protection of the gastrointestinal lining
